Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$27,000.00
Predicting Post-Transplant and Left Ventricular Assist Device Outcomes through Right Heart Catheterization in Patients with Advanced Heart Failure
FY 2024-25
Summary
Heart failure (HF) is a serious condition, affecting an increasing number of people each year. Patients with HF often struggle with everyday activities, such as dressing or washing, due to shortness of breath and fatigue. Unfortunately, treatment options for HF patients remain limited, and many patients will eventually need to be hospitalized and may not survive. For patients with advanced HF, a heart transplant is the best treatment. However, not all patients are good candidates for this treatment. Some HF patients have specific characteristics which increase their risk of post-transplant HF. Some of these characteristics include a diagnosis of pulmonary hypertension (PH), meaning they have abnormally high blood pressure in the vessels surrounding the heart. If a patient isnt eligible for transplant, a machine called a left ventricular assist device (LVAD) is often used as a bridge to transplantation, however, it can face similar post implant complications.Understanding why post-transplant/implant complications occur can help guide decision making for doctors. Our work aims to analyze signals from a diagnostic test called a right heart catheterization (RHC), and to identify tools that help us predict whether patients will suffer HF after a transplant or LVAD. Sometimes, administration of certain medications, known as pulmonary vasodilators, can reverse the high blood pressure in patients with PH. While currently only certain patients are eligible for such medication, we will be testing patients who meet a new threshold for medication to identify patients with irreversible PH. By studying how patients respond to these medications, and analyzing RHC data, we hope to help doctors make better decisions about the best treatments for people with advanced HF.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
529785
Name
Pankiw Maya S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Predicting Post-Transplant and Left Ventricular Assist Device Outcomes through Right Heart Catheterization in Patients with Advanced Heart Failure
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Heart Failure; Heart Transplant; Hemodynamics; Inhaled Nitric Oxide; Left Ventricular Assist Device; Pulmonary Hypertension; Pulmonary Vasodilator; Right Heart Catheterization; Rv:Pa Coupling; Sodium Nitroprusside
Abstract
Heart failure (HF) is a serious condition, affecting an increasing number of people each year. Patients with HF often struggle with everyday activities, such as dressing or washing, due to shortness of breath and fatigue. Unfortunately, treatment options for HF patients remain limited, and many patients will eventually need to be hospitalized and may not survive. For patients with advanced HF, a heart transplant is the best treatment. However, not all patients are good candidates for this treatment. Some HF patients have specific characteristics which increase their risk of post-transplant HF. Some of these characteristics include a diagnosis of pulmonary hypertension (PH), meaning they have abnormally high blood pressure in the vessels surrounding the heart. If a patient isnt eligible for transplant, a machine called a left ventricular assist device (LVAD) is often used as a bridge to transplantation, however, it can face similar post implant complications.Understanding why post-transplant/implant complications occur can help guide decision making for doctors. Our work aims to analyze signals from a diagnostic test called a right heart catheterization (RHC), and to identify tools that help us predict whether patients will suffer HF after a transplant or LVAD. Sometimes, administration of certain medications, known as pulmonary vasodilators, can reverse the high blood pressure in patients with PH. While currently only certain patients are eligible for such medication, we will be testing patients who meet a new threshold for medication to identify patients with irreversible PH. By studying how patients respond to these medications, and analyzing RHC data, we hope to help doctors make better decisions about the best treatments for people with advanced HF.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Pankiw, Maya S
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~